BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol 2020;190:508-19. [PMID: 32319084 DOI: 10.1111/bjh.16621] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Balakrishnan B, Kulkarni UP, Pai AA, Illangeswaran RSS, Mohanan E, Mathews V, George B, Balasubramanian P. Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1100306] [Reference Citation Analysis]
2 Vythoulkas D, Tsirigotis P, Griniezaki M, Konstantellos I, Lazana I. Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation. Cancers 2023;15:680. [DOI: 10.3390/cancers15030680] [Reference Citation Analysis]
3 Füssiová M, Švec P, Horáková J, Sedláček P, Rohoň P, Celec P, Boďová I, Adamčáková J, Sýkora T, Dobšinská V, Pozdechová M, Dóczyová D, Vargová S, Kolenová A. The Importance of New EBMT Criteria on the Diagnosis of Veno-Occlusive Liver Disease in Children. JCM 2023;12:826. [DOI: 10.3390/jcm12030826] [Reference Citation Analysis]
4 Ariagno S, Ragoonanan D, Khazal S, Mahadeo KM, Cisneros GS, Zinter MS, Blacken RA, Mohan G, Lehmann LE, Ferdjallah A, Mara KC, Kohorst MA. Prior COVID-19 infection may increase risk for developing endothelial dysfunction following hematopoietic cell transplantation. Front Oncol 2022;12:1000215. [PMID: 36733348 DOI: 10.3389/fonc.2022.1000215] [Reference Citation Analysis]
5 Schoettler ML, Saldana BD, Berkenkamp L, Chonat S, Watkins B, Rotz SJ, Simons D, Graf E, Rossi C, Cheng J, Hammers YA, Rytting H, Williams KM. Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy. Transplant Cell Ther 2023;29:45.e1-8. [PMID: 36202334 DOI: 10.1016/j.jtct.2022.09.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mohty M, Blaise D, Peffault de Latour R, Labopin M, Bourhis JH, Bruno B, Ceballos P, Detrait M, Gandemer V, Huynh A, Izadifar-Legrand F, Jubert C, Labussière-Wallet H, Lebon D, Maury S, Paillard C, Pochon C, Renard C, Rialland F, Schneider P, Sirvent A, Asubonteng K, Guindeuil G, Yakoub-Agha I, Dalle JH. Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study. Bone Marrow Transplant 2022. [PMID: 36564486 DOI: 10.1038/s41409-022-01900-6] [Reference Citation Analysis]
7 Niebergall-Roth E, Frank NY, Ganss C, Frank MH, Kluth MA. Skin-Derived ABCB5(+) Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine. Int J Mol Sci 2022;24. [PMID: 36613507 DOI: 10.3390/ijms24010066] [Reference Citation Analysis]
8 Wang W, Ye Y, Du Y, Xu Z, Yuan K, Wang Y, Adzraku SY, Li Y, Xu K, Qiao J, Ju W, Zeng L. EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation. Front Immunol 2022;13:1019657. [PMID: 36591312 DOI: 10.3389/fimmu.2022.1019657] [Reference Citation Analysis]
9 Radnay Z, Illés Á, Udvardy M, Prohászka Z, Sinkovits G, Csányi MC, Kellermayer M, Kiss A, Hársfalvi J. Von Willebrand Factor and Platelet Levels before Conditioning Chemotherapy Indicate Bone Marrow Regeneration following Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2022;28:830.e1-7. [PMID: 36058547 DOI: 10.1016/j.jtct.2022.08.028] [Reference Citation Analysis]
10 Putta S, Young BA, Levine JE, Reshef R, Nakamura R, Strouse C, Perales MA, Howard A, Pine P, Shi J, Zhang P, Ho VT, Saber W. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study. Transplant Cell Ther 2022:S2666-6367(22)01798-5. [PMID: 36574581 DOI: 10.1016/j.jtct.2022.11.024] [Reference Citation Analysis]
11 Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 2022:S2666-6367(22)01783-3. [PMID: 36442770 DOI: 10.1016/j.jtct.2022.11.015] [Reference Citation Analysis]
12 Moreno-Castaño AB, Salas MQ, Palomo M, Martinez-Sanchez J, Rovira M, Fernández-Avilés F, Martínez C, Cid J, Castro P, Escolar G, Carreras E, Diaz-Ricart M. Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development. Front Immunol 2022;13:1050994. [PMID: 36479117 DOI: 10.3389/fimmu.2022.1050994] [Reference Citation Analysis]
13 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 N. Magnani H. Danaparoid Sodium: A Review of Its Use in Hepatic Thrombotic Disorders. Anticoagulation - Current Perspectives 2022. [DOI: 10.5772/intechopen.103851] [Reference Citation Analysis]
15 Peci F, Dekker L, Pagliaro A, van Boxtel R, Nierkens S, Belderbos M. The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2022. [PMID: 35690693 DOI: 10.1038/s41409-022-01728-0] [Reference Citation Analysis]
16 Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol 2022;:JCO2102389. [PMID: 35439028 DOI: 10.1200/JCO.21.02389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Mohty M, Cluzeau T, Jubert C, Lawson S, Ryan RJ, Hanvesakul R, Perruccio K. Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. Bone Marrow Transplant 2022. [PMID: 35115668 DOI: 10.1038/s41409-022-01588-8] [Reference Citation Analysis]
18 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kozanoglu I, Pepedil-tanrikulu F. Functions of the endothelium and its role in hematopoietic cell transplantation. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kayikci O, Akpinar S, Tekgunduz E. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: a retrospective single center experience. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103369] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Akpinar S, Kayikci O, tekgunduz E. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103367] [Reference Citation Analysis]
22 de Azevedo JTC, Costa TCM, Lima KC, Maciel TT, Palma PVB, Darrigo-Júnior LG, Setanni Grecco CE, Stracieri ABPL, Elias JB, Pieroni F, Guerino-Cunha RL, Pinto ACS, De Santis GC, Covas DT, Hermine O, Simões BP, Oliveira MC, Malmegrim KCR. Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients. Front Immunol 2021;12:774442. [PMID: 34956203 DOI: 10.3389/fimmu.2021.774442] [Reference Citation Analysis]
23 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Toro JF, Peña E, Ramírez O, López P, Portilla CA, López-Medina E. Routine Use of Biomarkers to Rationalize Antibiotic Use During Febrile Episodes in Pediatric Bone Marrow Transplantation Units. Pediatr Infect Dis J 2021;40:1023-8. [PMID: 34636797 DOI: 10.1097/INF.0000000000003239] [Reference Citation Analysis]
25 Pereira M, Lee NT, Noonan J, Willcox AEH, Calvello I, Georgy SR, Selan C, Chia JS, Hauw W, Wang X, Peter K, Robson SC, Nandurkar HH, Sashindranath M. Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy. Front Immunol 2021;12:708554. [PMID: 34421913 DOI: 10.3389/fimmu.2021.708554] [Reference Citation Analysis]
26 Sallee CJ, Smith LS, Rowan CM, Heckbert SR, Angelo JR, Daniel MC, Gertz SJ, Hsing DD, Mahadeo KM, McArthur JA, Fitzgerald JC. Early Cumulative Fluid Balance and Outcomes in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients With Acute Respiratory Failure: A Multicenter Study. Front Oncol 2021;11:705602. [PMID: 34354951 DOI: 10.3389/fonc.2021.705602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lelas A, Greinix HT, Wolff D, Eissner G, Pavletic SZ, Pulanic D. Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease. Front Immunol 2021;12:676756. [PMID: 33995421 DOI: 10.3389/fimmu.2021.676756] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol 2021;8:e229-39. [PMID: 33636143 DOI: 10.1016/S2352-3026(20)30404-X] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodavsky I, O'Gorman P, Pagliuca A, Mo C, Baron RM, Aghemo A, Soiffer R, Fareed J, Carlo-Stella C, Richardson P. COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol 2021;193:43-51. [PMID: 33538335 DOI: 10.1111/bjh.17240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
30 Wu J, Fu HX, He Y, Mo XD, Liu X, Cai X, Gui RY, Liu HX, Yan CH, Chen YH, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2021;56:2097-107. [PMID: 33846561 DOI: 10.1038/s41409-021-01293-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Mezö B, Horváth O, Sinkovits G, Veszeli N, Kriván G, Prohászka Z. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation. Front Med (Lausanne) 2020;7:569291. [PMID: 33117830 DOI: 10.3389/fmed.2020.569291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]